Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme

NCT00001461 | Completed

• 2 other identifiers: 95009995-H-0099
• Study Type: observational
• Target: 209
• Locations: 1 country
• Sites: 1

Brief Summary

The walls of blood vessels are lined by flat cells that are responsible for releasing substance(s) that control the activity of the blood vessel. These cells are referred to as the endothelium of the blood vessel. One of the substances released from the endothelium is called nitric oxide (NO). This substance functions to keep blood vessels relaxed and to prevent blood from clotting inside the vessels. Studies done by researchers in the Cardiology Branch of the National Heart, Lung and Blood Institute have shown that nitric oxide activity may be lower in patients with hardening of the arteries (atherosclerosis) and risk factors for atherosclerosis. Another substance released by the cells of the endothelium is called bradykinin. It functions to stimulate the production of nitric oxide. Therefore bradykinin is also responsible for the relaxation and widening of blood vessels. An enzyme found in the blood called angiotensin-converting enzyme (ACE) inactivates baradykinin and thereby decreases the production of nitric oxide. The activity of ACE is determined by genetics and is different in each person. Medications that block ACE (ACE-inhibitors) may be useful for patients with high levels of ACE activity. This study is designed to determine;

1. 1.The role of bradkinin in stimulating the production of nitric oxide
2. 2.Whether ACE-inhibitors improve blood vessel relaxation caused by bradykinin
3. 3.Whether ACE-inhibitors improve abnormal blood vessel relaxation
4. 4.Whether ACE-inhibitors and bradykinin affect blood clotting
5. 5.Whether blood vessel response to ACE-inhibitor and bradykinin depends on the patients genetic make-up

Conditions

Atherosclerosis; Coronary Disease

Keywords

Angiotensin Converting Enzyme; Angiotensin Converting Enzyme Inhibitors; Bradykinin; Endothelial Function; Nitric Oxide; Coronary Artery Disease

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

Anyone with chest pain with known or suspected coronary artery disease.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI): lead

Study Sites (1)

National Heart, Lung and Blood Institute (NHLBI)

Bethesda, Maryland, 20892, United States

Location

Related Publications (1)

• Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993 May;87(5):1468-74. doi: 10.1161/01.cir.87.5.1468.

  PMID: 8491001 BACKGROUND

MeSH Terms

Conditions

Atherosclerosis; Coronary Disease; Coronary Artery Disease

Condition Hierarchy (Ancestors)

Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Myocardial Ischemia; Heart Diseases

Study Design

• Study Type: observational
• Sponsor Type: NIH

Study Record Dates

• First Submitted: November 3, 1999
• First Posted: December 10, 2002
• Study Start: March 1, 1995
• Study Completion: April 1, 2001
• Last Updated: March 4, 2008

Record last verified: 2000-04

Locations

US (1)